Now showing items 1381-1390 of 1412
Investment in the future of thrombosis and hemostasis science
(Wiley Periodicals, Inc., 2022-05)
Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases
(London Cancer North and EastWiley Periodicals, Inc., 2022-05)
The burden of HCC is substantial. To address gaps in HCC care, the American Association for the Study of Liver Diseases (AASLD) Practice Metrics Committee (PMC) aimed to develop a standard set of process-based measures and ...
Research methodologies to address clinical unmet needs and challenges in alcohol‐associated liver disease
(Wiley Periodicals, Inc.Springer, 2022-04)
Alcohol‐associated liver disease (ALD) is emerging worldwide as the leading cause of liver‐related morbidity, mortality, and indication for liver transplantation. The ALD Special Interest Group and the Clinical Research ...
Risk of variceal hemorrhage and pretransplant mortality in children with biliary atresia
(Wiley Periodicals, Inc., 2022-09)
Background and AimsThe natural history of gastroesophageal variceal hemorrhage (VH) in biliary atresia (BA) is not well characterized. We analyzed risk factors, incidence, and outcomes of VH in a longitudinal multicenter ...
Metabolic abnormalities, liver and body fat in American versus Chinese patients with non-alcoholic fatty liver disease
(Wiley Publishing Asia Pty Ltd, 2022-08)
Background and AimNon-alcoholic fatty liver disease (NAFLD) is common in the United States and China. We compared prevalence of metabolic syndrome (MS), hepatic steatosis and fibrosis, and quantity and quality of body fat ...
Trends in the inpatient burden of alcohol-related liver disease among women hospitalized in the United States
(Wiley Periodicals, Inc., 2022-07)
Alcohol-related liver disease (ALD) is the leading indication for liver transplantation in the United States, but disparities for women with ALD exist. We sought to characterize trends in ALD hospitalizations and mortality ...
Risk of HBV reactivation during therapies for HCC: A systematic review
(Wiley Periodicals, Inc.World Health Organization, 2022-05)
Background and AimsTreatment for HCC has evolved rapidly, but the risk of HBV reactivation to new therapies is unclear. We systematically reviewed data on HBV reactivation in patients receiving HCC therapy in relation to ...
The efficacy of culture-guided versus empirical therapy with high-dose proton pump inhibitor as third-line treatment of Helicobacter pylori infection: A real-world clinical experience
(Wiley Periodicals, Inc., 2022-10)
Background and AimMost consensuses recommend culture-guided therapy as third-line Helicobacter pylori treatment. This study aimed to investigate the efficacies of culture-guided therapy and empirical therapy with high-dose ...